Expression of P2X7 receptor increases in vivo tumor growth

Area of Science:

• Molecular Biology
• Oncology
• Immunology

Background:

• The P2X7 receptor (P2X7) is primarily known as an ATP-gated ion channel with cytotoxic functions.
• Emerging research suggests a potential role for P2X7 in regulating cell proliferation.
• Its specific contribution to tumor development in vivo remains largely unexplored.

Purpose of the Study:

• To investigate the role of the P2X7 receptor in promoting tumor growth and development in vivo.
• To identify the molecular mechanisms underlying P2X7-mediated tumor promotion.
• To assess the therapeutic potential of targeting P2X7 in cancer.

Main Methods:

• In vivo tumor models using human embryonic kidney cells engineered to express P2X7.
• Administration of P2X7 inhibitors (oxidized ATP), VEGF-blocking antibodies (Avastin/bevacizumab), and P2X7 silencing.
• Assessment of tumor growth, proliferation, apoptosis, vascularization (VEGF), and NFATc1 activation via immunohistochemistry.

Main Results:

• P2X7 expression significantly enhanced tumor tumorigenicity, proliferation, and anaplastic phenotype in vivo.
• P2X7-expressing tumors exhibited increased vascularization, elevated VEGF secretion, and higher levels of activated NFATc1.
• Inhibition of P2X7, blockade of VEGF, or P2X7 silencing effectively suppressed tumor growth and neoangiogenesis.
• Strong P2X7 expression was observed in several human cancers.

Conclusions:

• The P2X7 receptor actively promotes tumor growth, proliferation, and neoangiogenesis in vivo.
• Targeting P2X7 or its downstream pathways (VEGF, NFATc1) represents a viable therapeutic strategy for cancers exhibiting P2X7 positivity.